---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-089281"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:50:42.256021+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma Q2 net loss $26.9M; LIFT-AD topline data expected Sept 2024

## Summary
- Cash, cash equivalents and investments were $91.8M as of June 30, 2024, down from $147.4M at Dec 31, 2023.
- Net loss of $26.9M ($0.70 per share) for Q2 2024 vs. $29.6M ($0.78 per share) in Q2 2023.
- R&D expenses $22.2M (up from $21.6M) driven by ATH-1105 Phase 1 trial; G&A down to $5.9M from $10.0M.
- Topline data from Phase 2/3 LIFT-AD trial of fosgonimeton in Alzheimer's targeted for September 2024; full data at CTAD in October.
- Phase 1 trial of oral ATH-1105 for ALS underway; first cohort completed, expected completion by year-end 2024.

## SEC filing metadata
- accession: 0000950170-24-089281
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017024089281/0000950170-24-089281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017024089281/atha-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-089281
- JSON: https://secwatch.observer/filing/0000950170-24-089281.json
- Plain text: https://secwatch.observer/filing/0000950170-24-089281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.